REG-Arix Bioscience PLC Notice of Results and Investor Presentation

Arix BioscienceAnnouncement

14/04/2023 12:00

============

   Arix Bioscience PLC (ARIX)
   Notice of Results and Investor Presentation

   14-Apr-2023 / 12:00 GMT/BST

   ════════════════════════════════════════════════════════════════════════════

                                         

                               Arix Bioscience plc

                                         

                   Notice of Results and Investor Presentation

   LONDON, 14 April 2023: Arix Bioscience  plc (“Arix” or the “Company”)  (LSE:
   ARIX), a  transatlantic  venture capital  company  focused on  investing  in
   breakthrough biotechnology companies, will announce its results for the full
   year ended 31 December 2022 on Thursday 20 April 2023.

   Analyst Briefing: 10:00am BST, Thursday 20 April 2023

   Management will  host a  virtual briefing  for Analysts  at 10:00am  BST  on
   Thursday 20 April. Analysts wishing  to join should register their  interest
   by contacting Powerscourt on  1 arix@powerscourt-group.com or on +44 (0)  20
   7290 1050.

   Investor Presentation: 4:00pm BST, Thursday 20 April 2023

   Management will  be hosting  a live  presentation and  Q&A session  via  the
   online platform, Investor Meet Company, at  4:00pm BST on Thursday 20  April
   2023.

   The presentation  is  open  to  analysts  and  all  existing  and  potential
   shareholders. Questions can  be submitted  pre-event via  the Investor  Meet
   Company dashboard or at any time during the live presentation via the "Ask a
   Question" function.

   Investors  can   sign  up   to   Investor  Meet   Company  for   free   via:
    2 https://www.investormeetcompany.com/arix-bioscience-plc/register-investor

   Investors who already follow Arix on the Investor Meet Company platform will
   automatically receive an invitation to the event.

    

                                       ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 3 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    4 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is  a transatlantic venture  capital company focused  on
   investing  in  breakthrough  biotechnology  companies  around   cutting-edge
   advances in life sciences.

    

   We collaborate  with  exceptional  entrepreneurs and  provide  the  capital,
   expertise, and networks to  help accelerate their  ideas into important  new
   treatments for patients.  As a  listed company, we  are able  to bring  this
   exciting growth  phase of  our industry  to a  broader range  of  investors.
    5 www.arixbioscience.com

    

    

   ════════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ════════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  NOR
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   237071
   EQS News ID:    1608089


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    6 fncls.ssp?fn=show_t_gif&application_id=1608089&application_name=news&site_id=refinitiv

References

   Visible links
   1. mailto:arix@powerscourt-group.com
   2. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=4d118b3300aa96332de7879ede8cb917&application_id=1608089&site_id=refinitiv&application_name=news
   3. mailto:charlotte@arixbioscience.com
   4. mailto:arix@powerscourt-group.com
   5. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1608089&site_id=refinitiv&application_name=news


============